Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322758478> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4322758478 endingPage "277" @default.
- W4322758478 startingPage "268" @default.
- W4322758478 abstract "Zoledronic acid (5 mg; ZOL), a once-yearly bisphosphonate, reduces osteoporotic fractures and increases bone mineral density (BMD). This 3-year post-marketing surveillance examined its real-world safety and effectiveness.This prospective, observational study included patients who started ZOL for osteoporosis. Data were assessed at baseline, 12, 24, and 36 months for safety and effectiveness. Treatment persistence, potentially related factors, and persistence before and after the COVID-19 pandemic started were also investigated.The safety analysis and effectiveness analysis sets included 1406 and 1387 patients, respectively, with mean age of 76.5 years. Adverse reactions (ARs) occurred in 19.35% of patients, with an acute-phase reaction in 10.31, 1.01, and 0.55% after the first, second, and third ZOL infusions. Renal function-related ARs, hypocalcaemia, jaw osteonecrosis, and atypical femoral fracture occurred in 1.71, 0.43, 0.43, and 0.07% of patients, respectively. Three-year cumulative fracture incidences were 4.44% for vertebral, 5.64% for non-vertebral, and 9.56% for clinical fractures. BMD increased by 6.79, 3.14, and 1.78% at the lumbar spine, femoral neck, and total hip, respectively, after 3-year treatment. Bone turnover markers remained within reference ranges. Treatment persistence was 70.34% over 2 years and 51.71% over 3 years. Male, age ≥ 75 years, no previous medicines for osteoporosis, no concomitant medicines for osteoporosis, and inpatient at the first infusion were related to discontinuation. There was no significant difference in the persistence rate between before and after the COVID-19 pandemic (74.7% vs. 69.9%; p = 0.141).This 3-year post-marketing surveillance confirmed the real-world safety and effectiveness of ZOL." @default.
- W4322758478 created "2023-03-03" @default.
- W4322758478 creator A5006064157 @default.
- W4322758478 creator A5010022067 @default.
- W4322758478 creator A5018787693 @default.
- W4322758478 creator A5035301035 @default.
- W4322758478 creator A5065288428 @default.
- W4322758478 creator A5087785772 @default.
- W4322758478 date "2023-03-01" @default.
- W4322758478 modified "2023-10-16" @default.
- W4322758478 title "Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance" @default.
- W4322758478 cites W1486043180 @default.
- W4322758478 cites W1993035292 @default.
- W4322758478 cites W2030203316 @default.
- W4322758478 cites W2095741166 @default.
- W4322758478 cites W2118460365 @default.
- W4322758478 cites W2123816368 @default.
- W4322758478 cites W2163830908 @default.
- W4322758478 cites W2510312052 @default.
- W4322758478 cites W2603588112 @default.
- W4322758478 cites W2967986241 @default.
- W4322758478 cites W2977403162 @default.
- W4322758478 cites W3094957610 @default.
- W4322758478 cites W3144961751 @default.
- W4322758478 cites W3160142138 @default.
- W4322758478 cites W3199709069 @default.
- W4322758478 doi "https://doi.org/10.1007/s00774-023-01410-5" @default.
- W4322758478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36862212" @default.
- W4322758478 hasPublicationYear "2023" @default.
- W4322758478 type Work @default.
- W4322758478 citedByCount "0" @default.
- W4322758478 crossrefType "journal-article" @default.
- W4322758478 hasAuthorship W4322758478A5006064157 @default.
- W4322758478 hasAuthorship W4322758478A5010022067 @default.
- W4322758478 hasAuthorship W4322758478A5018787693 @default.
- W4322758478 hasAuthorship W4322758478A5035301035 @default.
- W4322758478 hasAuthorship W4322758478A5065288428 @default.
- W4322758478 hasAuthorship W4322758478A5087785772 @default.
- W4322758478 hasBestOaLocation W43227584781 @default.
- W4322758478 hasConcept C126322002 @default.
- W4322758478 hasConcept C141071460 @default.
- W4322758478 hasConcept C197934379 @default.
- W4322758478 hasConcept C2775854910 @default.
- W4322758478 hasConcept C2776326535 @default.
- W4322758478 hasConcept C2776541429 @default.
- W4322758478 hasConcept C2776886416 @default.
- W4322758478 hasConcept C2777251235 @default.
- W4322758478 hasConcept C2777308945 @default.
- W4322758478 hasConcept C2778715236 @default.
- W4322758478 hasConcept C2779384505 @default.
- W4322758478 hasConcept C68312169 @default.
- W4322758478 hasConcept C71924100 @default.
- W4322758478 hasConceptScore W4322758478C126322002 @default.
- W4322758478 hasConceptScore W4322758478C141071460 @default.
- W4322758478 hasConceptScore W4322758478C197934379 @default.
- W4322758478 hasConceptScore W4322758478C2775854910 @default.
- W4322758478 hasConceptScore W4322758478C2776326535 @default.
- W4322758478 hasConceptScore W4322758478C2776541429 @default.
- W4322758478 hasConceptScore W4322758478C2776886416 @default.
- W4322758478 hasConceptScore W4322758478C2777251235 @default.
- W4322758478 hasConceptScore W4322758478C2777308945 @default.
- W4322758478 hasConceptScore W4322758478C2778715236 @default.
- W4322758478 hasConceptScore W4322758478C2779384505 @default.
- W4322758478 hasConceptScore W4322758478C68312169 @default.
- W4322758478 hasConceptScore W4322758478C71924100 @default.
- W4322758478 hasFunder F4320312288 @default.
- W4322758478 hasIssue "2" @default.
- W4322758478 hasLocation W43227584781 @default.
- W4322758478 hasLocation W43227584782 @default.
- W4322758478 hasLocation W43227584783 @default.
- W4322758478 hasOpenAccess W4322758478 @default.
- W4322758478 hasPrimaryLocation W43227584781 @default.
- W4322758478 hasRelatedWork W1769645042 @default.
- W4322758478 hasRelatedWork W2023234727 @default.
- W4322758478 hasRelatedWork W2042156239 @default.
- W4322758478 hasRelatedWork W2072567035 @default.
- W4322758478 hasRelatedWork W2141615036 @default.
- W4322758478 hasRelatedWork W2189065230 @default.
- W4322758478 hasRelatedWork W2321314049 @default.
- W4322758478 hasRelatedWork W2375316322 @default.
- W4322758478 hasRelatedWork W2619961008 @default.
- W4322758478 hasRelatedWork W4221038394 @default.
- W4322758478 hasVolume "41" @default.
- W4322758478 isParatext "false" @default.
- W4322758478 isRetracted "false" @default.
- W4322758478 workType "article" @default.